HAE Insider Trading

Insider Ownership Percentage: 1.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $3,031,094.99

Haemonetics Insider Trading History Chart

This chart shows the insider buying and selling history at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Haemonetics Share Price & Price History

Current Price: $62.54
Price Change: Price Decrease of -0.1 (-0.16%)
As of 04/29/2025 11:16 AM ET

This chart shows the closing price history over time for HAE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$62.55Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for Haemonetics (NYSE:HAE)

99.67% of Haemonetics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at HAE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$61Mbought$1.57MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1B$0$1BTotal InflowsTotal Outflows
Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More on Haemonetics

Today's Range

Now: $62.54
Low: $62.37
High: $63.24

50 Day Range

MA: $62.80
Low: $55.89
High: $68.70

52 Week Range

Now: $62.54
Low: $55.30
High: $97.97

Volume

15,362 shs

Average Volume

686,851 shs

Market Capitalization

$3.14 billion

P/E Ratio

24.68

Dividend Yield

N/A

Beta

0.41

Who are the company insiders with the largest holdings of Haemonetics?

Haemonetics' top insider shareholders include:
  1. Michelle L Basil (EVP)
  2. Anila Lingamneni (EVP)
  3. Josep Llorens (EVP)
  4. Stewart W Strong (Insider)
Learn More about top insider investors at Haemonetics.

Who are the major institutional investors of Haemonetics?

Haemonetics' top institutional investors include:
  1. Boston Trust Walden Corp — 2.23%
  2. Allspring Global Investments Holdings LLC — 1.92%
  3. Fort Washington Investment Advisors Inc. OH — 1.03%
  4. Schwartz Investment Counsel Inc. — 0.75%
  5. Peregrine Capital Management LLC — 0.32%
  6. Rhumbline Advisers — 0.32%
Learn More about top institutional investors of Haemonetics stock.

Which institutional investors are selling Haemonetics stock?

Within the last quarter, HAE stock was sold by these institutional investors:
  1. Harbor Capital Advisors Inc.
  2. New York State Teachers Retirement System
  3. Amalgamated Bank
  4. Yousif Capital Management LLC
  5. Riverwater Partners LLC
Within the last year, company insiders that have sold Haemonetics company stock include:
  1. Michelle L Basil (EVP)
  2. Anila Lingamneni (EVP)
  3. Josep Llorens (EVP)
  4. Stewart W Strong (Insider)
Learn More investors selling Haemonetics stock.

Which institutional investors are buying Haemonetics stock?

During the previous quarter, HAE stock was bought by institutional investors including:
  1. Fort Washington Investment Advisors Inc. OH
  2. Schwartz Investment Counsel Inc.
  3. Boston Trust Walden Corp
  4. Allspring Global Investments Holdings LLC
  5. Confluence Investment Management LLC
  6. Skylands Capital LLC
  7. Peregrine Capital Management LLC
  8. GAMMA Investing LLC